Literature DB >> 6336560

The effects of subclass on the ability of anti-phosphocholine antibodies to protect mice from fatal infection with Streptococcus pneumoniae.

D E Briles1, C Forman, S Hudak, J L Claflin.   

Abstract

We have compared the abilities of IgG1, IgG2b, and IgG3 antibodies to protect mice against infection with a bacterial pathogen for which antibody-mediated protection is thought to be a function of killing by phagocytes rather than complement-mediated lysis. For this study, we used anti-phosphocholine (PC) antibodies of the T15 idiotype, since they are known to have very similar binding sites and have the ability to protect mice from Streptococcus pneumoniae infection. Our results indicated that antibodies with the three different IgG constant regions gave similar degrees of protection. This finding was surprising, since earlier data showed a strong restriction of anti-carbohydrate and anti-PC antibodies to the IgG3 subclass. Our data raise the possibility that the restriction of most immune responses to particular IgG subclasses may be more to allow isotype-specific regulation than to utilize special effector functions of different IgG isotypes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6336560

Source DB:  PubMed          Journal:  J Mol Cell Immunol        ISSN: 0724-6803


  15 in total

Review 1.  Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors:  C G Vinuesa; C de Lucas; M C Cook
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

2.  Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on toll-like receptor 2.

Authors:  Abdul Q Khan; Quanyi Chen; Zheng-Qi Wu; James C Paton; Clifford M Snapper
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.

Authors:  David Verhoeven; Sheldon Perry; Michael E Pichichero
Journal:  Clin Vaccine Immunol       Date:  2014-05-21

4.  Peptide mimic of phosphorylcholine, a dominant epitope found on Streptococcus pneumoniae.

Authors:  S L Harris; M K Park; M H Nahm; B Diamond
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres.

Authors:  K Allaoui-Attarki; S Pecquet; E Fattal; S Trollé; E Chachaty; P Couvreur; A Andremont
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

6.  Dendritic cell-derived exosomes express a Streptococcus pneumoniae capsular polysaccharide type 14 cross-reactive antigen that induces protective immunoglobulin responses against pneumococcal infection in mice.

Authors:  Jesus Colino; Clifford M Snapper
Journal:  Infect Immun       Date:  2006-10-16       Impact factor: 3.441

7.  Cross-reactive monoclonal antibodies for diagnosis of pneumococcal meningitis.

Authors:  W D Waltman; B Gray; L S McDaniel; D E Briles
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

8.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

9.  Monoclonal phosphorylcholine antibody binds to beta-lipoprotein from different animal species.

Authors:  U B Sørensen
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

10.  Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.

Authors:  J H van de Wijgert; A F Verheul; H Snippe; I J Check; R L Hunter
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.